Skip to content
Medical Health Aged Care

Avania Appoints Innovative Operations Strategist Charlene Dark as New Chief Operating Officer

Avania 2 mins read
BILTHOVEN, Netherlands & BOSTON--BUSINESS WIRE--

Avania, the leading global MedTech advisory and clinical development partner, today announced the appointment of operational strategy expert Charlene Dark as chief operating officer (COO).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203677092/en/

Charlene Dark, newly appointed chief operating officer of Avania. (Photo: Business Wire)

Charlene Dark, newly appointed chief operating officer of Avania. (Photo: Business Wire)

Dark brings over 30 years of experience driving forward-thinking, risk-based strategies that fuel growth and profitability in the clinical development sector. She previously served as executive vice president of global clinical analytics at Clinipace, now Caidya, where she successfully drove commercial growth and operational efficiency of its global clinical analytics solution and spearheaded the development and adoption of the data aggregation and analytics offering.

“I am honored to step into the role of Avania’s COO and work alongside such a talented and dedicated team,” said Dark. “As we navigate the evolving needs of the MedTech industry, my focus will be on fostering innovation and aligning our operations to meet immediate challenges while positioning Avania for sustainable long-term success. Leveraging my experience in implementing actionable strategies and driving measurable outcomes, I am excited to help shape the future of MedTech advisory and development, reinforcing Avania’s reputation as the industry standard.”

“As Avania guides sponsors through every stage of their product’s life cycle, Charlene’s data-driven decision-making, grounded in extensive clinical development experience, will be an asset to our clients and team,” Jason Monteleone, Avania president and CEO, said. “She plays a critical role in our next phase of growth supporting a flexible operating model that meets the diverse needs of our sponsors.”

About Avania

Avania is the leading global MedTech advisory and clinical development partner with a focus on medical devices, diagnostics/IVDs, and digital health. Core offerings include full service clinical research outsourcing, market access, reimbursement, regulatory, and product development advisory services. Avania’s vision is to be your trusted global partner in the evolution of your medical technology from innovation to commercialization to improving patient health and well-being. When you need to advance your medical technology, It Takes Avania.


Contact details:

Holli Kroeker
+1 308-338-2358
[email protected]

Media

More from this category

  • Community, Medical Health Aged Care
  • 08/12/2025
  • 04:15
Save Our Sons Duchenne Foundation

Global Clinical Experts Gather in Sydney to Advance Adult Duchenne Muscular Dystrophy Care

Key Facts: Life expectancy for Australians living with DMD have increased from 18 for those borne before 1970, to around 30 today. As adult care remains fragmented and inconsistent between hospitals and States, the Symposium will develop global multi-disciplinary care recommendations.MEDIA RELEASE A world-first International Symposium dedicated toimproving multi-disciplinary clinical care for adults living with Duchenne muscular dystrophy (DMD) will take place in Sydney over the next three days. Hosted by the Save Our Sons Duchenne Foundation, the invitation-only event will bring together more than 35 of the world’s leading clinicians and researchers to develop the first multidisciplinary, global best-practice…

  • Contains:
  • Medical Health Aged Care
  • 07/12/2025
  • 01:41
Takeda Pharmaceutical Company Limited

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline NEWARK,…

  • Medical Health Aged Care
  • 06/12/2025
  • 02:11
Arthur D. Little

Arthur D. Little and Vega IT Unveil Joint Venture for Digital Innovation

NEW YORK–BUSINESS WIRE– Arthur D. Little (ADL) and Vega IT today announced the formation of Axceler8 Solutions, a 50/50 joint venture created to design,…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.